SLU-PP-332 Structure
Molecular formula: | C18H14N2O2 |
Molecular weight: | 290.32 g/mol |
CAS number: | 303760-60-3 |
Synonyms |
|
Research Applications: |
|
SLU-PP-332 Overview
SLU-PP-332 is a synthetic agonist for estrogen-related orphan receptors (ERRฮฑ, ERRฮฒ, and ERRฮณ), with its strongest potency at ERRฮฑ (EC50 โ 98 nM). It binds directly to the ligand-binding domain of these receptors, driving a transcriptional program linked to fat metabolism and mitochondrial energy production in skeletal muscle [R].
Ongoing research has explored the possibility of using SLU-PP-332 or analogs to address obesity, insulin resistance, and cardiac dysfunction. SLU-PP-332 is classified as an exercise mimetic, meaning it reproduces certain changes linked to physical activity without increasing actual movement.
Mitochondrial Effects
Studies show that SLU-PP-332 increases mitochondrial respiration and mitochondrial biogenesis, raising the concentration of oxidative fibers in muscle cells. Mice treated with the compound displayed higher expression of enzymes involved in oxidative phosphorylation and more extensive succinate dehydrogenase staining, indicating a shift toward greater aerobic metabolism [R].
In Vivo Findings
In rodent models, SLU-PP-332 boosts endurance capacity on treadmill tests while also promoting weight control, even in animals maintained on high-fat diets. Researchers have reported an increase in running time and distance in normal-weight mice, suggesting an exercise-like effect on skeletal muscle performance. The compound modulates muscle fiber composition, favoring oxidative type IIa fibers that maintain prolonged activity and resist fatigue [R].
In experiments with diet-induced obese andย ob/obย mice, SLU-PP-332 treatment raised whole-body energy expenditure and boosted fatty acid oxidation, which reduced fat mass and improved insulin sensitivity. Researchers observed a drop in body weight for subjects on high-fat diets, with no major effect on food intake. The compound shifted metabolic parameters toward a more aerobic profile, mirroring exercise-induced benefits on muscle and fat tissue. These findings suggest that SLU-PP-332 may be a useful strategy for countering obesity and metabolic syndrome in vivo [R].